<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493712</url>
  </required_header>
  <id_info>
    <org_study_id>IBD98-M-2002</org_study_id>
    <nct_id>NCT02493712</nct_id>
  </id_info>
  <brief_title>A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M</brief_title>
  <official_title>A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M Delayed-release Capsules to Induce Remission in Patients With Active, Mild to Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holy Stone Healthcare Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>inVentiv Health Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Holy Stone Healthcare Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed&#xD;
      Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the&#xD;
      clinical efficacy of IBD98-M delayed release capsules (in a fixed combination) over a 6-week&#xD;
      treatment period and 2 weeks follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study IBD98-M-2002 is a Phase 2a, multicenter, randomized, double-blind, parallel-group,&#xD;
      placebo-controlled study in patients with active, mild to moderate UC. It is being conducted&#xD;
      as an exploratory proof of concept study to investigate the clinical efficacy of IBD98-M&#xD;
      delayed-release capsules (in a fixed combination) over a 6-week treatment period and a 2-week&#xD;
      follow-up period.&#xD;
&#xD;
      Patients will be screened for study enrollment up to 4 weeks prior to randomization (Visit&#xD;
      3). During the screening period, patients will be evaluated by conducting laboratory tests,&#xD;
      physical examination, and sigmoidoscopy. To be eligible, patients are to have a score of ≥4&#xD;
      and ≤10 on the UCDAI, and a score of ≥1 on the UCDAI endoscopy subscore. In addition, the&#xD;
      diagnosis of UC must be confirmed by endoscopic and histologic evidence in the past; if prior&#xD;
      confirmation is not available, this must be done at the time of screening endoscopy. After&#xD;
      the screening visits, eligible patients will be randomized to 1 of 3 study groups: (1) IBD98&#xD;
      M 0.8 g/day (mesalamine 0.8 g with sodium hyaluronate 92 mg), (2) IBD98 M 1.2 g/day&#xD;
      (mesalamine 1.2 g with sodium hyaluronate 138 mg), or (3) placebo. Up to 51 patients will be&#xD;
      enrolled in this study (including drop-out patients), with 17 patients randomized to each&#xD;
      treatment group. Patients will be encouraged to take their medication at the same time every&#xD;
      day.&#xD;
&#xD;
      During the study, patients will visit the clinic on 7 occasions: 2 visits during the&#xD;
      screening period (the second screening visit is the baseline visit); 4 visits during the&#xD;
      treatment period, Visits 3, 4, 5, and 6/early termination at Weeks 0, 2, 4, and 6; and 1&#xD;
      visit at the end of the follow-up period, Visit 7 at Week 8. Patients will record the&#xD;
      dates/times of dosing (after randomization), concomitant medication, and symptoms and adverse&#xD;
      events (AEs) in a daily diary starting at Visit 1 and continuing until the end of treatment&#xD;
      (Visit 6/early termination). Rescue medication will not be permitted during the 6 weeks of&#xD;
      the treatment period, and patients who are considered to not be benefiting from the therapy&#xD;
      can be withdrawn and assigned an appropriate alternative UC treatment by the Investigator.&#xD;
      Compliance will be assessed throughout the study by determining the amount of unused&#xD;
      medication. Records will be kept of all medication dispensed, used, and returned by each&#xD;
      patient. At the end of the study, all unused trial medication and used packaging will be&#xD;
      returned to the Sponsor. All study medication will be accounted for and any discrepancies&#xD;
      documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage of patients in remission over a 6-week treatment period. Remission is defined as a modified UCDAI (Ulcerative Colitis Disease Activity Index) score of ≤1, with a score of 0 for rectal bleeding and stool frequency, no mucosal friability, and sigmoidoscopy score not exceeding 1).&#xD;
Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.&#xD;
Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day&gt; normal), score 2 (3-4/day &gt;normal), score 3 (&gt;4/day&gt; normal) Mucosal appearance: score 1 (Erythema, decreased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical improvement over a 6-weeks treatment period was defined as a ≥ 3 point reduction from Baseline in the modified UCDAI (Ulcerative Colitis Disease Activity Index ) score.&#xD;
Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.&#xD;
Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day&gt; normal), score 2 (3-4/day &gt;normal), score 3 (&gt;4/day&gt; normal) Mucosal appearance: score 1 (Erythema, decrased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose, twice a day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose, twice a day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose</intervention_name>
    <description>6 capsules of IBD98-M, twice a day</description>
    <arm_group_label>High dose</arm_group_label>
    <other_name>Mesalamine-Sodium Hyaluronic 200 mg-23 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose</intervention_name>
    <description>4 capsules of IBD98-M</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Mesalamine-Sodium Hyaluronic 200 mg-23 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo: C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, age ≥18 and &lt;75 years, suffering from UC for at least 6 months prior&#xD;
             to screening&#xD;
&#xD;
          2. Female patients must be postmenopausal, sterile, or have a negative urine pregnancy&#xD;
             test prior to entering the study and use adequate contraception during the study if of&#xD;
             childbearing potential.&#xD;
&#xD;
          3. Diagnosis of active UC with UCDAI ≥4 and ≤10, with endoscopy score of ≥1 in the UCDAI&#xD;
             mucosal appearance subscore&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with Crohn's disease, indeterminate colitis, or ischemic colitis&#xD;
&#xD;
          2. Female patients who are pregnant or breastfeeding&#xD;
&#xD;
          3. Ulcerative proctitis with ≤15 cm of disease&#xD;
&#xD;
          4. Patients with infectious colitis as determined by assessment for Clostridium difficile&#xD;
             (C. difficile) and fecal pathogens at screening or treatment for C. difficile within&#xD;
             30 days prior to screening&#xD;
&#xD;
          5. History of or current evidence of toxic megacolon, fulminant colitis (e.g., Lichtiger&#xD;
             score of ≥10), colonic perforation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvio Danese</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <results_first_submitted>March 9, 2020</results_first_submitted>
  <results_first_submitted_qc>August 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2020</results_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02493712/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02493712/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Started recruitment on 2016/01/01 Completed recruitment on 2018/07/01</recruitment_details>
      <pre_assignment_details>No patient was excluded before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High Dose</title>
          <description>High dose, twice a day for 6 weeks.&#xD;
High dose: 6 capsules of IBD98-M, twice a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo: C</title>
          <description>Placebo, twice a day&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="P3">
          <title>Low Dose</title>
          <description>Low dose, twice a day for 6 weeks&#xD;
Low dose: 4 capsules of IBD98-M</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled patients were included.</population>
      <group_list>
        <group group_id="B1">
          <title>High Dose</title>
          <description>High dose, twice a day for 6 weeks.&#xD;
High dose: 6 capsules of IBD98-M, twice a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo: C</title>
          <description>Placebo, twice a day&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Low Dose</title>
          <description>Low dose, twice a day for 6 weeks&#xD;
Low dose: 4 capsules of IBD98-M</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" lower_limit="22" upper_limit="69"/>
                    <measurement group_id="B2" value="47.5" lower_limit="21" upper_limit="69"/>
                    <measurement group_id="B3" value="35" lower_limit="20" upper_limit="54"/>
                    <measurement group_id="B4" value="45" lower_limit="20" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="12.23"/>
                    <measurement group_id="B2" value="45.8" spread="12.21"/>
                    <measurement group_id="B3" value="36.6" spread="10.68"/>
                    <measurement group_id="B4" value="41.9" spread="12.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UC remission</title>
          <description>remission was defined as having a modified Ulcerative Colitis Disease Activity Index [UCDAI] score of ≤1, with a score of 0 for rectal bleeding and stool frequency, no mucosal friability, and a sigmoidoscopy score not exceeding 1</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission Rate</title>
        <description>Percentage of patients in remission over a 6-week treatment period. Remission is defined as a modified UCDAI (Ulcerative Colitis Disease Activity Index) score of ≤1, with a score of 0 for rectal bleeding and stool frequency, no mucosal friability, and sigmoidoscopy score not exceeding 1).&#xD;
Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.&#xD;
Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day&gt; normal), score 2 (3-4/day &gt;normal), score 3 (&gt;4/day&gt; normal) Mucosal appearance: score 1 (Erythema, decreased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)</description>
        <time_frame>6 weeks</time_frame>
        <population>The percentage of patients in remission at Week 6 is summarized for the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Group</title>
            <description>IBD98-M 1.2 g/day group</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Group</title>
            <description>IBD98-M 0.8 g/day group</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule, 6 capsules/day</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Rate</title>
          <description>Percentage of patients in remission over a 6-week treatment period. Remission is defined as a modified UCDAI (Ulcerative Colitis Disease Activity Index) score of ≤1, with a score of 0 for rectal bleeding and stool frequency, no mucosal friability, and sigmoidoscopy score not exceeding 1).&#xD;
Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.&#xD;
Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day&gt; normal), score 2 (3-4/day &gt;normal), score 3 (&gt;4/day&gt; normal) Mucosal appearance: score 1 (Erythema, decreased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)</description>
          <population>The percentage of patients in remission at Week 6 is summarized for the ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement Rate</title>
        <description>Clinical improvement over a 6-weeks treatment period was defined as a ≥ 3 point reduction from Baseline in the modified UCDAI (Ulcerative Colitis Disease Activity Index ) score.&#xD;
Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.&#xD;
Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day&gt; normal), score 2 (3-4/day &gt;normal), score 3 (&gt;4/day&gt; normal) Mucosal appearance: score 1 (Erythema, decrased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Group</title>
            <description>IBD98-M 1.2 g/day group</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Group</title>
            <description>IBD98-M 0.8 g/day group</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo capsule, 6 capsules/day</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement Rate</title>
          <description>Clinical improvement over a 6-weeks treatment period was defined as a ≥ 3 point reduction from Baseline in the modified UCDAI (Ulcerative Colitis Disease Activity Index ) score.&#xD;
Modified UCDAI scoring system is sum of following 4 subscores (parameters). Higher score means worst disease condition.&#xD;
Rectal bleeding: score 1 (Streaks of blood), score 2 (obvious blood), score 3 (Mostly Blood) Stool frequency: score 1 (1-2/day&gt; normal), score 2 (3-4/day &gt;normal), score 3 (&gt;4/day&gt; normal) Mucosal appearance: score 1 (Erythema, decrased vascular pattern, Minimal granularity), score 2 (Marked erythema, Friability, Granularity, Absent vascular pattern, Bleeding minimal trauma, No ulcerations), score 3 (Ulceration Spontaneous bleeding) Physician's Global Assessment: score 1 (mild), score 2 (Moderate), score 3 (Severe)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 8 weeks - 6 weeks treatment and 2 weeks follow-up</time_frame>
      <desc>The gastro disorder is not the high risk for mortality</desc>
      <group_list>
        <group group_id="E1">
          <title>High Dose Group</title>
          <description>IBD98-M 1.2 g/day group</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Group</title>
          <description>IBD98-M 0.8 g/day group</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo capsule, 6 capsules/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>WORSENING OF ULCERATIVE COLITIS</sub_title>
                <description>(N)Gastrointestinal disorders&#xD;
Colitis ulcerative&#xD;
WORSENING OF ULCERATIVE COLITIS</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <description>Colitis ulcerative</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Abdominal pain</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dyspesia</sub_title>
                <description>Dyspesia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>vomiting</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>YUCHIH, Chen</name_or_title>
      <organization>Holy Stone Healthcare Co., Ltd</organization>
      <phone>886287975966 ext 272</phone>
      <email>ivychen@hshc.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

